OHRP News and Press, Ohr Pharmaceutical Inc.

Company expects to initiate trading on NASDAQ Under Ticker Symbol “NBSE” effective July 15, 2019 Company completes previously announced financing of approximately $9 million immediately prior to closing of the merger  Greenlight Capital agrees to purchase ~9% of Ne...

NEW YORK, July 10, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (“Ohr”) (Nasdaq: OHRP) today announced that all proposals related to its proposed merger with NeuBase Therapeutics, Inc. (“NeuBase”) were approved by Ohr’s stockholders at a special meeti...

Gainers:  Oasmia Pharmaceutical OASM  +76% . Xenetic Biosciences (NASDAQ: XBIO ) +41% . Tyme Technologies TYME  +22% . Gol Linhas Aereas Inteligentes S.A. GOL  +19% . BIOLASE (NASDAQ: BIOL ) +16% . OHR Pharmaceutical (NASDAQ: OHRP ) +15% . Cool Holdings (NASDAQ: AWSM...

-- Of the Votes Received to Date, More than 99% Are Voting in Favor of the Merger Proposal -- More Votes Are Needed to Reach 50% of the Outstanding Shares to Go Forward with the Special Meeting -- Every Vote Is Important to Avoid Delay in Completion of the Merger NEW YORK, July 03, ...

PITTSBURGH, May 16, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today announced that it has designated four experienced executives from the biotechnology in...

Ohr Pharmaceutical (NASDAQ: OHRP ): Q2 GAAP EPS of -$0.40. More news on: OHR Pharmaceutical, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) (the “Company” or “Ohr”) today reported financial results for the three and six month periods ended March 31, 2019. "We continue to be excited by the opportunity to merge with N...

PITTBURGH, Pa., March 11, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address rare genetic diseases, today announced that it has entered into definitive agreements for a $9.0 million...

Seelos Therapeutics (NASDAQ: SEEL ) +55%  on acquisition an exclusive license to intellectual property owned by The Regents of the University of California. More news on: Seelos Therapeutics Inc, Bio-Path Holdings, Inc., Altimmune, Inc., Stocks on the move, Read more ...

CORAL GABLES, FL / ACCESSWIRE / March 6, 2019 / The tech stock market has been a hotbed of exciting conversation during the last few months as a result of word spreading about tech companies taking innovative approaches to create new technologies for the betterment of humankind. Stemming f...